Abcam and Shuwen extend strategic alliance in China to develop companion diagnostics
SVP Marketing at Abcam
Jay Z. Zhang
CEO and Chairman of Shuwen
Under the terms of the agreement, Abcam will provide highly specific recombinant rabbit monoclonal antibodies and the associated commercial development rights to Shuwen. Shuwen will complete the required immunohistochemical verification and develop the companion diagnostic kits. Abcam will obtain milestone payments linked to kit development and subsequent sales. Specific financial details are not being disclosed.
In 2018, the two parties signed a memorandum of understanding to explore combining the expertise of both parties to design, develop, and commercialize immunohistochemistry-based companion diagnostic kits to meet the growing demand of the pharmaceutical industry. In the past two years, the two parties have worked together successfully on both PD-L1 and Claudin 18.2 kits.